Dislipidemia market to slump 60% as cheap statins undercut new drugs

Sales of statins are forecast to drop from $13.7 billion in 2012 to $5.5 billion in 2021, despite retaining a 59% share of the dislipidemia patient population. The sales slump will be due to payers pushing for generic usage and the low switching costs associated with this, according to new analysis by Datamonitor Healthcare, Forecast: Dislipidemia .